Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Intended Use
VZV IgG (CSF) assayis intended for in vitro diagnosis of VZV associated diseases, namelyvaricella and herpes zoster, including their neurological complications, i.e.encephalitis, meningitis, cerebellitis, vacsulitis, myelitis or inflammatory neuropathies. The diagnostic kit can also be utilized for differential diagnosis of neuro infections, infections of eye and skin exanthematous diseases.
Contents of Kit
1. ELISA break-away strips (blue)
2. Calibrator 1
3. Calibrator 2
4. Calibrator 3
5. Calibrator 4
6. Calibrator 5
7. Calibrator 6
8. Anti-human IgG antibodies
9. Wash buffer
10. Dilution buffer
11. Chromogenic substrate
12. Stop solution
Store the kit reagents at 2-8°C. For longer period make aliquots and keep them at -20°C. Avoid repeated thawing and freezing. For more detailed information, please download the following document on our website
Intraassay variability: 2.7-8.7%
Interassay variability: 9.7-10%
Detection Limit
The detection limit of the test is 0.2 mIU.


Have you cited DEIA472 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Disseminated herpes simplex virus and varicella zoster virus co-infection in a patient with idiopathic thrombocytopenic purpura


Authors: Bergqyist, Christina; Aad, Yasmin Abi; Nassar, Dany; El Zein, Saeed; Kanj, Souha S.

Concomitant disseminated herpes simplex virus (HSV) and varicella zoster virus (VZV) infection is a rare event. We describe a case of disseminated HSV and VZV infection in an 80-year-old patient many years after splenectomy for idiopathic thrombocytopenic purpura (ITP). This is the first case of disseminated HSV-1 and VZV infection with molecular evidence of the simultaneous presence of both viruses in two different body sites (the skin and cerebrospinal fluid). This adds to the three reports of patients developing cutaneous disseminated herpes zoster multiple years after splenectomy for ITP. (C) 2018 The Authors. Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences.

Varicella-zoster virus as a causative agent of acute retinal necrosis in younger patients


Authors: Xu, Hai-Yan; Li, Meng-Da; Ye, Jun-Jie; Zhao, Chan; Hu, Yun-Tao; Di, Yu

Background: Herpes virus is considered to be the pathogen of acute retinal necrosis (ARN) infection. Previous studies have found that patients with ARN caused by the varicella-zoster virus (VZV) are often older, and patients with herpes simplex virus (I ISV) induced ARN are considerably younger. However, in our clinical work, we find that VZV is also a pathogen in younger ARN patients. We, therefore, aimed to analyze the common etiology of younger ARN patients. Methods: A retrospective analysis was made of 20 eyes (18 patients) diagnosed as having ARN in the Department of Ophthalmology of Peking Union Medical College Hospital from 2014 to 2016. All patients were reviewed for demographic data, clinical course, clinical manifestations, rime from onset to initial physician visit, duration of follow-up, visual acuity at both presentation and final visit, and treatment strategies. A paired t test was used to compare visual acuity between the presenting vision and those of final follow-up. Vitreous or aqueous specimens from 18 eyes of 18 patients were analyzed with multiplex polymerase chain reaction (mPCR)/quantitative PCR (qPCR) and xTAG-liquid chip technology (xTAG-LCT) to determine the causative virus of ARN. Results: Final best visual acuity (BCVA) improved significantly from 1.36 +/- 0.95 (median 20/400) to 0.95 +/- 0.82 (median 20/100) (t=2.714, P=0.015) after systemic and intravitreal antiviral treatment combined with or without pars plana vitrectomy. PCR and xTAG-LCT results showed four of the five samples in the younger group (32.2 +/- 5.2 years) and 12 of the 13 samples in the senior group (53.6 +/- 4.9 years) were positive for VZV, and two of the five samples in the younger group were positive for HSV-1. Conclusions: This study demonstrates that VZV is also a common causative virus for ARN in younger patients. Considering this finding, a systemic antiviral treatment protocol should be immediately changed to intravenous ganciclovir when the patient does not respond to acyclovir before determining the causative virus, especially in younger patients.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket